LGALS9 and colorectal carcinoma: Another study showed that in KRAS mutant cells, LGALS9 acts as a lysosomal inhibitor, suppressing the fusion of autophagosomes with lysosomes, leading to the accumulation of autophagosomes, excessive swelling of lysosomes, and cell death, offering a potential therapeutic avenue for anti-tumor treatment of CRC (27).